Sinovac Biotech Ltd
-
Open
7.86
-
Previous Close
7.89
-
Volume (Avg)
24.83k (57.04k)
-
Day's Range
7.85-7.97
-
52Wk Range
4.60-8.75
-
Market Cap.
449.88M
-
Dividend Rate ( Yield)
-
-
Beta
0.09
-
Shares Outstanding
57.02M
-
P/E Ratio (EPS)
23.92 (0.32)
Top Stories
-
BRIEF-Sinovac Resumes Production And Operation At Its Beijing's Quality Assurance Department
Reuters 2 days ago* SINOVAC BIOTECH LTD - PRODUCTION OF INLIVE, LOCATED AT SINOVAC BEIJING’S CHANGPING SITE WAS NOT AFFECTED BY EVENTS OF APRIL 17, 2018 Source text for Eikon: Further company coverage: Our Standards:The Thomson Reuters Trust Principles.
-
Global Pediatric Vaccines Market Overview 2017-2026: Sinovac Biotech Ltd, Serum Institute of India Pvt Ltd
MarketWatch -
Sinovac Biotech (SVA) Reports Prelim. Results of Phase 3 Clinical Study on Sabin Inactivated Polio Vaccine (sIPV)
StreetInsider -
Sinovac Biotech : Announces Preliminary Results of Phase III Trial on sIPV
4-Traders -
Sinovac Bio in (literal) tussle with activist investor
Seeking Alpha 4/19/2018Literally defining "activist investor," Sinovac Biotech (NASDAQ:SVA) says it has never refused to share its financial statements with Shandong Sinobioway subsidiary Sinobioway Biomedicine Co., Ltd., owner of 26.91% of Sinovac's outstanding stock.
-
BRIEF-Sinovac Biotech Issues Statement In Response To Statements By Shandong Sinobioway Biomedicine Co Ltd
Reuters -
Sinovac Biotech : Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.
4-Traders -
Polio Vaccines Market - Global Industry Insights, 2025
openpr.com -
Sinovac Resumes Production and Operation at Sinovac Beijing's Quality Assurance Department
Markets Insider -
Sinovac Biotech reports preliminary results of phase III trial on Sabin inactivated polio vaccine
Pharmabiz -
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
WMBF News -
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
ABC6 -
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
FOX5 Las Vegas -
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
WAND -
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
14 NEWS 4/19/2018BEIJING, April 19, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated ...
-
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
KFVS12 -
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
WRCB -
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
KHQ-Q6
